



PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

| | | | |
|--|--|--------------------------|--|
| (51) International Patent Classification 7 : C12N 15/12, C07K 14/705, C12N 15/62, A61K 38/17 | | A1 | (11) International Publication Number: WO 00/63372 (43) International Publication Date: 26 October 2000 (26.10.00) |
| (21) International Application Number: | PCT/GB00/01456 | | (81) Designated States: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG). |
| (22) International Filing Date: | 17 April 2000 (17.04.00) | | |
| (30) Priority Data: | 9908807.2 | 16 April 1999 (16.04.99) | GB |
| (71) Applicant (<i>for all designated States except US</i>): | CELLTECH THERAPEUTICS LIMITED [GB/GB]; 216 Bath Road, Slough, Berkshire SL1 4EN (GB). | | |
| (72) Inventors; and | | | |
| (75) Inventors/Applicants (<i>for US only</i>): | LAWSON, Alastair, David, Griffiths [GB/GB]; Holden Farm, Cheriton, Alresford, Hampshire SO2 0NX (GB). FINNEY, Helene, Margaret [GB/GB]; 64 Clare Road, Maidenhead, Berkshire SL6 4DQ (GB). | | |
| (74) Agents: | MERCER, Christopher, Paul et al.; Carpmaels & Ransford, 43 Bloomsbury Square, London WC1A 2RA (GB). | | |

(54) Title: SYNTHETIC SIGNALLING MOLECULES

(57) Abstract

The invention relates to synthetic signalling molecules, which are based on sequences derived from primary signalling motifs such as immunoglobulin tyrosine receptor-based activation motifs (ITAMs). The use of such signalling molecules within chimeric receptor proteins allows one to tailor the level of intracellular signalling mediated by the chimeric receptor. Proteins containing, and nucleic acids encoding, such synthetic signalling molecules suitable for use in medicine, are described.

The remaining pages of this document are provided in electronic format on the attached compact disc.

Full paper copies will be provided upon request by the Examiner.